Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion Mutations

November 25th 2021

Before closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.

Dr. Leal on Developments Made in EGFR Exon 20–Mutant NSCLC Treatment

November 24th 2021

Ticiana Leal, MD, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer.

Treatment of Advanced NSCLC With Dual Immune Checkpoint Inhibitors: 4-Year Update of CheckMate 227

November 24th 2021

Sandip P. Patel, MD, reviews updates on dual immunotherapy agents for the treatment of advanced NSCLC including the 4-year update from the CheckMate 227 study.

Treatment of Advanced NSCLC With Immune Checkpoint Inhibitors

November 24th 2021

Drs Vamsidhar Velcheti, Ani Balmanoukian, Heather Wakelee, and Stephen Liu discuss recent updates on single-agent immunotherapy regimens in patients with NSCLC.

Advances in Diagnostics and Therapeutics Propel Interventional Pulmonology Forward

November 23rd 2021

Nathaniel Ivanick, MD, FCCP, discusses the evolution of interventional pulmonology, the benefits of robotic navigational bronchoscopy and other novel technologies in the field, and ongoing research that could further push the paradigm forward.

Sintilimab Combo Reduces Risk of Progression by 54% in EGFR-Mutated Nonsquamous NSCLC

November 22nd 2021

The addition of sintilimab to a bevacizumab biosimilar and pemetrexed/cisplatin resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with EGFR-mutated, nonsquamous non–small cell lung cancer who progressed after an EGFR TKI.

Mobocertinib Provides Treatment Option for EGFR Exon 20–Mutant NSCLC

November 20th 2021

Joel Neal, MD, PhD, discusses the evolving treatment landscape for patients with EGFR exon 20–mutant non–small cell lung cancer.

Third SARS-CoV2 Vaccine Shows Evidence of Seroconversion in Lung Cancer

November 19th 2021

Three doses of the SARS-CoV2 vaccine were shown to be safe and effective in patients with lung cancer, particularly in those with minimal serologic response after receiving only 2 doses.

Dr. Moutafi on the Results of a Study Evaluating Biomarkers of Resistance in NSCLC

November 19th 2021

Myrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

November 19th 2021

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Pralsetinib Approved in Europe for RET Fusion+ Advanced NSCLC

November 19th 2021

The European Commission has granted a conditional marketing authorization to pralsetinib for use as a single agent in adult patient with RET fusion–positive advanced non–small cell lung cancer who did not previously receive a RET inhibitor.

Future Outlook

November 19th 2021

Melissa Suk Heist, MD, MPH, and Solange Peters, MD, PhD, reflect on treatments being developed in the non-small cell lung cancer space that they are excited for and provide some key takeaways and advice for colleagues.

Treating ALK-Mutant and KRAS G12C–Mutant NSCLC

November 19th 2021

Lung cancer experts share updates in the treatment of ALK-mutant NSCLC and KRAS G12C–mutant NSCLC as seen in the CROWN study, BrigALK2 real-world study, and CODEBreaK 100 study.

Treatment of MET Exon 14 Mutations in NSCLC

November 19th 2021

Heather Wakelee, MD, reviews key data for the treatment of MET exon 14 mutations in NSCLC as seen in the GeoMETry-III trial and the CRYSALIS study.

Other Agents Targeting EGFR Exon 20 Insertion Mutations in NSCLC

November 18th 2021

Experts briefly review a number of other agents in NSCLC that target EGFR exon 20 insertion mutations.

Key Differences Between Amivantamab and Mobocertinib in NSCLC

November 18th 2021

Shared insight on the differences between amivantamab and mobocertinib and when they may be appropriately used in patients with NSCLC.

Dr. Reidy-Lagunes on the Results of the SPINET Study by Tumor Subtype in BP-NETs

November 17th 2021

Diane Reidy-Lagunes, MD, discusses the results of the phase 3 SPINET trial by tumor subtype in bronchopulmonary neuroendocrine tumors.

Experts Chip Away at Resistance, Sequencing, and Targeted Therapy Selection in Lung Cancer

November 17th 2021

Edgardo Santos, MD, discusses the current state of targeted therapies for EGFR- and ALK-positive non–small cell lung cancer, as well as immunotherapy in stage III NSCLC, and management strategies in small cell lung cancer.

Dr. Langer on the Evolution of Molecular Testing in Advanced NSCLC

November 15th 2021

Corey J. Langer, MD, professor of medicine, University of Pennsylvania, director, Thoracic Oncology, Penn Medicine, discusses the evolution of molecular testing in advanced non–small cell lung cancer.